CV Sciences ((CVSI)) has held its Q1 earnings call. Read on for the main highlights of the call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
CV Sciences’ latest earnings call painted a cautiously optimistic picture, with management emphasizing operational gains despite stubborn top-line pressure and a tight liquidity position. Executives highlighted margin expansion, leaner costs, improving adjusted EBITDA, and a move to positive operating cash flow, arguing these trends set a constructive path toward eventual profitability even as revenue and regulatory risks linger.
Revenue Resilience Despite Headwinds
CV Sciences reported Q1 2026 revenue of $3.2 million, down 11% year over year but only 3% lower than Q4 2025, underscoring a degree of resilience in a still-contracting CBD category. Management framed the modest sequential decline as evidence that the business is stabilizing in a difficult regulatory and competitive landscape, even if growth remains elusive.
Improved Gross Margin Year-over-Year
Gross margin improved to 48.9% in Q1 2026 from 46.0% a year earlier, a 2.9-point expansion driven by lower product costs and early benefits from bringing more manufacturing in-house. While margins slipped from 50.5% in Q4 2025, the year-over-year gain signals structural progress that management expects to build on as insourcing scales.
Meaningful Cost Reductions
Operating expenses fell roughly 13.3% to $1.9 million, reflecting cuts in legal and professional fees, trimmed marketing, and broader administrative efficiencies. These reductions helped offset softer sales and show CV Sciences is actively reshaping its cost base to fit a smaller, more disciplined operating footprint.
Adjusted EBITDA and Cash Flow Improvement
Adjusted EBITDA loss narrowed to just $0.1 million from a $0.3 million loss a year ago, marking another step toward breakeven on a core earnings basis. The company also posted about $0.1 million of positive operating cash flow, reversing prior-year cash usage and demonstrating that cost actions are translating into real cash improvements.
Progress Toward Breakeven and Balance Sheet Moves
Management said the company is edging closer to sustainable cash-flow breakeven, ending Q1 with roughly $0.3 million in cash, slightly above year-end levels despite the tough backdrop. CV Sciences also amended a note payable into a convertible structure, a move aimed at preserving flexibility as it works through near-term liquidity constraints.
Product and Channel Momentum
The company is leaning into innovation with the launch of PlusHLTH EMPOWR, a non-cannabinoid product featuring 20 grams of protein, 5 grams of creatine, and probiotics, and teased additional launches for 2026. Direct-to-consumer sales remained robust at 44% of revenue, and management cited encouraging early feedback from both consumers and retailers on the new health-oriented offerings.
Strategic M&A and Operational Insourcing
Recent acquisitions of Cultured Foods and Elevated Softgels are beginning to build scale, diversify the portfolio, and enhance supply chain flexibility across formats and ingredients. Management expects further cost savings and faster time-to-market as manufacturing is increasingly insourced, with acquisition-related synergies targeted to ramp meaningfully in the second half of 2026.
Market Position and Emerging Regulatory Tailwinds
Despite category pressures, CV Sciences maintained its status as the No. 1 hemp extract brand in natural product retail channels, according to SPINS data cited on the call. Federal developments, including a new benefits program and an enforcement-discretion signal from regulators, were highlighted as early signs of potential regulatory tailwinds and new distribution avenues for compliant products.
Inventory and Working Capital Management
Inventory declined to $3.9 million from $4.1 million at year-end 2025, reflecting tighter oversight of purchasing and production. Management also pointed to better collections and more disciplined payables management as part of a broader effort to conserve cash and improve working capital efficiency.
Top-Line Pressure and Unit Sales Decline
Beneath the operational gains, demand remains soft, with revenue down 11% year over year and unit sales off roughly 12%. Management acknowledged that category-wide weakness and shifting consumer behavior are weighing on volumes, underscoring the need for share gains and diversification into non-cannabinoid products to stabilize growth.
Sequential Gross Margin Compression
While gross margin improved year over year, the drop from 50.5% in Q4 2025 to 48.9% in Q1 2026 signaled ongoing margin volatility. Management attributed the sequential compression to mix and transitional factors and reiterated confidence that further insourcing and scale benefits can support margins over time.
Widening GAAP Net Loss
On a GAAP basis, net loss widened to $0.6 million from $0.1 million in the prior-year quarter, revealing that headline profitability has not yet caught up with underlying operational improvements. The divergence between GAAP results and adjusted metrics will remain a focal point for investors as the company works to translate efficiency gains into bottom-line progress.
Operating Loss Despite Structural Cost Cuts
CV Sciences reported an operating loss of $0.3 million versus a small operating profit in the prior-year period, though management stressed that last year’s result benefited from a one-time $0.5 million payroll tax accrual reversal. Excluding that anomaly, the company believes recurring operating performance has improved meaningfully due to structural cost reductions.
Low Cash and Liquidity Risk
The company’s roughly $0.3 million cash balance remains low in absolute terms, and management conceded that modest cash usage is possible in the near term. This thin cushion keeps financing risk on the radar, even as cost discipline, working capital management, and note restructuring aim to stretch available liquidity.
Regulatory Uncertainty and Product Risk
Management cautioned that inconsistent federal guidance and pending legislative outcomes could force changes to certain products or restrict aspects of the current lineup. Such shifts could disrupt execution and weigh on revenue, reinforcing the importance of regulatory monitoring and flexible product design as the landscape evolves.
Competitive and Contracting Market
The CBD market remains fragmented, intensely competitive, and contracting, which management described as both a headwind and a consolidation opportunity. To navigate this environment, CV Sciences is focused on defending share in its core channels while using acquisitions and innovation to expand into adjacent health and wellness categories.
Guidance and Outlook
Looking ahead, CV Sciences reiterated that it is approaching cash-flow breakeven and expects to generate positive operating cash flow in the second half of 2026, fueled by continued cost cuts, insourcing, and synergies from recent deals. Management plans to launch additional non-cannabinoid products, expand select international markets, and pursue new program-driven opportunities, with more tangible benefits anticipated into late 2026 and 2027.
CV Sciences’ earnings call showcased a company reshaping its cost structure and product mix to fit a tougher market, with clear progress in margins, cash flow, and operational discipline. While liquidity is tight and the CBD category remains pressured and regulation in flux, management is betting that diversification, acquisitions, and manufacturing efficiencies can eventually convert today’s incremental gains into sustainable profitability.